Back to search

Article

Galcanezumab Add-on in Refractory Cluster Headache

2024-05-23

Abstract excerpt

<title>Abstract</title> <p><italic>Background:</italic> Cluster headache (CH), currently one of the most painful conditions, lacks a well-established, disease specific, and mechanism-based prophylactic treatment. Galganezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, reduced the weekly attacks of CH in one randomized, placebo-controlled trial for the prevention of episodic CH (eCH), bu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b57551bc-68c4-5126-af6c-afaa135f098d
DOI
10.21203/rs.3.rs-4390027/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Galcanezumab Add-on in Refractory Cluster HeadacheDOI 10.21203/rs.3.rs-4390027/v1
Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients With Migraine: 3 CasesSemantic proximity
Predictors of galcanezumab response in a real-world study of Korean patients with migraineSemantic proximity
Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UKSemantic proximity
Cluster headache: new targets and options for treatmentSemantic proximity
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity
Unveiling the Efficacy and Safety of Erenumab, a Monoclonal Antibody Targeting Calcitonin Gene-related Peptide (CGRP) Receptor, in Patients with Chronic and Episodic Migraine: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Clinical Trials with Subgroup AnalysisSemantic proximity
Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-AnalysisSemantic proximity
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – An updated systematic review and meta-analysisSemantic proximity
Erenumab in highly therapy-refractory migraine patients First German Real-world evidenceSemantic proximity
Cgrp Monoclonal Antibodies: Key Lessons from Real World EvidenceSemantic proximity
Safety and Efficacy of Fremanezumab for the Prevention of Migraine: a Meta-analysis from Random Clinical TrailsSemantic proximity
Effectiveness and Tolerability of Anti-Calcitonin Gene-related Peptide Therapy for Migraines and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USASemantic proximity
Select a neighboring publication to make it the new centre.